Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.42 |
| ▸ | CDK4 | P11802 | 5/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488212 | 0.88 | GSK3B (0.50) | GSK3BCDK4KDREIF2AK2MKNK1 | |
| SCHEMBL5875496 | 0.88 | CSNK1D (0.45) | GSK3BCDK4MAPK8MAPK9CSNK1D | |
| SCHEMBL6500869 | 0.85 | CDK4 (0.42) | GSK3BCDK4KDRMAPK8MAPK9 | |
| SCHEMBL6498415 | 0.82 | MAPK8 (0.46) | GSK3BCDK4KDREIF2AK2MAPK8 | |
| SCHEMBL6501882 | 0.78 | MAPK8 (0.43) | GSK3BCDK4MAPK8MAPK9 | |
| SCHEMBL5388522 | 0.77 | MAPK14 (0.56) | GSK3BCDK4MAPK8MAPK9CSNK1D | |
| SCHEMBL5875531 | 0.74 | MAPK14 (0.54) | GSK3BCDK4MAPK8MAPK9CSNK1D | |
| SCHEMBL5214934 | 0.74 | EIF2AK2 (0.51) | GSK3BCDK4EIF2AK2MAPK8MAPK9 | |
| SCHEMBL6108267 | 0.74 | GSK3B (0.51) | GSK3BCDK4KDREIF2AK2MKNK1 | |
| SCHEMBL5220849 | 0.74 | EIF2AK2 (0.50) | GSK3BEIF2AK2MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | GSK3B 3047/4885CDK4 439/4885KDR 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.